Navigation Links
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
Date:8/26/2008

INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced data presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., showing additional antiangiogenic activity of vascular-targeted PI3 kinase (PI3K) inhibitor SF1126, by blocking both VEGF and Bv8 signaling.

PI3K is part of a very powerful pathway, the PI3/AKT /mTOR pathway that has been shown to play a major role in cancer. Studies have shown that by inhibiting this pathway, tumor growth can be suppressed.

SF1126, a vascular targeted pan-PI3K inhibitor conjugate currently in Phase I clinical trials, was shown to block the pAKT pathway through which the angiogenic factors VEGF and Bv8 are involved. Bv8 is a recently identified protein that, like VEGF, plays a role in the angiogenic process and can significantly upregulate pAKT levels thereby supporting tumor growth.

In vitro inhibition of the PI3K/AKT/mTOR pathway by SF1126 was demonstrated to impede the ability of angiogenic stimulants VEGF and Bv8 to activate AKT in a dose dependant manner in two cancer cell lines (786-0 -- renal cell and PC3 prostate) and one endothelial cell line (HBEC -- human brain endothelial cells). Inhibiting Bv8 with antibodies has also been shown by others to have antitumor effects in mouse xenograft models.

"SF1126 could have additional impact in treating cancer where Bv8 is an important component of angiogenesis," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to targeting angiogenesis, SF1126 blocks key targets involved in tumor growth including mTOR, DNA-PK, PIM-1 and PLK-1. This adds another layer of versatility to what SF1126 can do as an antitumor agent."

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

About SF1126

There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer

growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients.

SF1126, is a proprietary small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTOR, DNA-PK, PLK-1,CK2, ATM and PIM-1 kinases all known to be involved in the cascade of chemical signals that control cell division. Importantly, SF1126 is designed as a dual inhibitor of both angiogenesis and cell proliferation. SF1126 is engineered to target and bind to specific integrins (alpha gamma beta 3) that are expressed on the surface of new tumor vasculature and within the tumor endothelial compartment. In tumor xenograph models Semafore demonstrated enhanced drug uptake of SF1126 which was directly attributable to the alpha gamma beta 3 targeted moiety. SF1126 is water soluble, has favorable pharmacokinetics and is well tolerated.

SF1126 is currently in Phase I clinical trials in both solid tumors and multiple myeloma.

For more information see the company's Web site at http://www.SemaforePharma.com.


'/>"/>
SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
3. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
4. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
7. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
8. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
9. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
10. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... JERUSALEM , May 23, 2016 ... therapies for the treatment of cancer and orphan genetic ... of up to $4.4 million from the Israel Innovation ... the Israeli Ministry of Economy and Industry. The mission ... and entrepreneurship in various industries, including science and technology, ...
Breaking Medicine Technology:
(Date:5/24/2016)... IL (PRWEB) , ... May 24, 2016 , ... To ... created a new research award to examine gender differences in lung cancer. Today, the ... Research Innovation Project: Lung Cancer in Women Award, funded by the American Lung Association’s ...
(Date:5/24/2016)... California (PRWEB) , ... May 24, 2016 , ... ... technology, debuted a new corporate identity and website at its “Transforming Outcomes” User ... and other marketing enhancements reflect i2i’s ongoing success to set the market standard ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of ... will ever be totally eliminated, many human performance problems can be prevented. , How ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Regenerative Medicine ... breakthroughs in adult stem cell therapy technology, protocols and patient results as have been ... field to become a more accessible standard of care for patients worldwide. , As ...
Breaking Medicine News(10 mins):